The fate of 4-hydroxycarbazole metabolite: metabolism and carcinogenicity assessment of a β-adrenergic receptor modulator containing carbazole structure

4区 · 医学

Article

作者: Minxia M. He ; Chad Hadden ; Ron Lantz ; Robert J. Barbuch ; Tao Ji ; August Wilke ; Kristina Campanale

LY377604 has a potential to form 4-hydroxycarbazole, which was reported in the literature as a mutagen. This safety concern led to our investigation of the metabolism and carcinogenicity of LY377604. In in vitro studies with LY377604, 4-hydroxycarbazole was detected in the presence of liver microsomes prepared from different species. When incubated with liver slices, only the conjugate of 4-hydroxycarbazole was detected. Subsequent in vivo radio-labelled studies were conducted to characterise the formation of 4-hydroxycarbazole from LY377604. Free 4-hydroxycarbazole was not detected in vivo, but the O-glucuronide conjugate was identified as a minor metabolite in urine samples, representing 0.2% and 0.9% of the radioactive dose in rats and monkeys. The low level of circulating 4-hydroxycarbazole glucuronide conjugate was also detected in plasma. LY377604 was negative in all genetic toxicology assays and was not associated with tumour induction in a 6-month carcinogenicity study using RasH2+/- mouse model. The exposure to free 4-hydroxycarbazole was not measurable after one dose and was about 0.1%-0.2% of the parent exposure at the end of the 6-month study. These data suggested that 4-hydroxycarbazole was formed as a minor metabolite in vivo, but it was primarily conjugated and excreted in urine as the glucuronide conjugate. The absence of tumours in the carcinogenicity study combined with the exposure data suggested that the low level of free 4-hydroxycarbazole did not represent a carcinogenic risk.

100 项与 LY-377604 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12858

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肥胖	临床2期	美国	Eli Lilly & Co.	2009-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00993421 (CTgov)	临床2期	肥胖	343	Placebo LY377604 (Placebo)	襯鏇選簾願鹽夢觸築獵(廠齋鹹窪窪觸範夢範餘) = 醖觸糧構餘築遞網鹹觸鬱選築遞構鏇築簾範夢 (憲積繭構鹽窪壓積衊繭, 膚壓網製鬱餘遞餘糧簾 ~ 積襯繭蓋選繭蓋鬱鑰築) 更多	-	2011-06-02
				Placebo Metoprolol+LY377604 (LY377604 (75 mg))	襯鏇選簾願鹽夢觸築獵(廠齋鹹窪窪觸範夢範餘) = 鏇範鹽範餘醖鹹鬱壓積鬱選築遞構鏇築簾範夢 (憲積繭構鹽窪壓積衊繭, 鹽壓願夢糧繭繭憲廠醖 ~ 積遞積齋廠廠積鏇獵積) 更多